Last reviewed · How we verify
NCT04199624
Assessment of Gastric pH Changes Induced by Ascorbic Acid Tablets
Phase 1 trial testing Omeprazole 20mg in Hypochlorhydria in 11 participants. Completed in 7 June 2023.
7 June 2023
Quick facts
| Lead sponsor | Indiana University |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 11 |
| Start date | 1 October 2021 |
| Primary completion | 7 June 2023 |
| Estimated completion | 7 June 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Omeprazole 20mg — full drug profile →
- Vitamin C — full drug profile →
Conditions studied
- Hypochlorhydria — all drugs for Hypochlorhydria →
Sponsor
Indiana University
Who can join
Adults 18 to 30, male only, with Hypochlorhydria. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the use of ascorbic acid, vitamin C, to temporary reduce gastric pH in individuals with omeprazole induced hypochlorhydria. All participants will receive ascorbic acid tablets to measure the change in gastric pH.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04199624
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Omeprazole 20mg
Trials testing the same drug.
- NCT04333407 — Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled · NA · terminated
- NCT03908619 — A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis · Phase 4 · unknown
- NCT03291249 — Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM · Phase 2 · withdrawn
- NCT03238534 — Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS · Phase 4 · completed
- NCT03378960 — Study to Compare the Bioavailability of Omeprazole 20 mg Before and After Undergoing Surgery for Morbid Obesity · Phase 4 · completed
Other Indiana University trials
Trials by the same sponsor.
- NCT07470086 — The Role of Environmental Temperatures in Respiratory Control · NA · not yet recruiting
- NCT07470099 — The Role of Breathing Perception in Respiratory Control · NA · not yet recruiting
- NCT07179952 — Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) · Phase 2 · not yet recruiting
- NCT07070804 — Maternal Biomarkers and Environmental Contributors to Autism Spectrum Disorders in Children of First-time Mothers · not yet recruiting
- NCT07499583 — Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04199624 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Indiana University
- Last refreshed: 22 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04199624.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing